Skip to main content
Premium Trial:

Request an Annual Quote

Mitomics, QDx Ink Development, Marketing Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitochondrial DNA diagnostic test firm Mitomics today announced that QDx Pathology Services will develop, market, and process the QPredict Prostate Mitomic Test.

The test will be based on Mitomics' Prostate Core Mitomic Test, which Mitomics launched in March. Under the non-exclusive agreement, QDx Pathology will leverage its network of pathologists, urologists, and processing centers to expand the availability of the technology in the US.

Financial and other terms of the deal were not disclosed.

The Prostate Core Mitomic Test uses mitochondrial DNA to detect the presence or absence of cancerous cells by using previously obtained prostate biopsy tissue and "its cancerization field effect" to detect molecular changes and missed tumors. According to a study published in the journal Prostate Cancer and Prostatic Diseases in January 2010, the PCR-based test achieved sensitivity of 84 percent and a negative predictive value of 91 percent.

"We believe the Mitomic Technology is an important piece of the puzzle in detecting prostate cancer in patients with initial negative biopsies," M.N. Qureshi, president and medical director of QDx Pathology, said in a statement. "We believe that facilitating the early detection of low volume prostate cancer, should, in turn, lead to more definitive treatment."

Based in Thunder Bay, Ontario, Mitomics transitioned from an R&D shop to a commercial entity last year. QDx is a national, full-service clinical and anatomic pathology laboratory and is based in Cranford, NJ.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.